Psychedelics MGC Pharma gets permission from Slovenian health authorities to research psilocybin MGC says it is the first company operating in Slovenia to obtain permission to engage in studies on the psychedelic compound Rowan DunneApril 5, 2023
Psychedelics Dutch government establishes MDMA research commission The commission will be investigating the risks and benefits associated with MDMA-assisted therapy Rowan DunneMarch 31, 2023
Psychedelics Psilocybin access denied to patients despite ongoing lawsuit against Health Canada Eight patients sued the government at the end of July last year over what they believe is a violation of constitutional rights Rowan DunneMarch 24, 2023
News Lucy Scientific and Wesana Health partner to develop CBD and psilocybin-based drug 'SANA-013' is a proprietary therapy intended to treat conditions like migraines, episodic cluster headaches and MDD Rowan DunneMarch 22, 2023
Psychedelics Optimi Health secures MDMA and psilocybin distribution agreement in Australia The company will supply Mind Medicine Australia with the substances, now considered designated therapies in the country Rowan DunneMarch 1, 2023
Psychedelics Awakn Life Sciences helps establish psychedelics clinics in Portugal Awakn will also be providing its clinical protocols and training to Portuguese clinicians in a 10-year agreement Rowan DunneFebruary 22, 2023
News Lucy Scientific Discovery applies for Health Canada approval to produce cocaine and heroin The move is intended to reduce harm from adulterated drugs and fentanyl Rowan DunneFebruary 17, 2023
Psychedelics Psyched Wellness formulates first commercial Amanita muscaria extract The cartoon-like toadstool is psychoactive, has medicinal properties and lives in a symbiotic relationship with certain trees Rowan DunneFebruary 9, 2023
Psychedelics Optimi Health submits clinical trial application after developing proprietary MDMA drug The drug will be used to help establish a safe supply for patients in Canada and Australia Rowan DunneFebruary 7, 2023
Psychedelics Woke Pharma and Swinburne U partner for Australia’s biggest psilocybin trial The AUD$5M study will involve about 160 participants and aims to help combat treatment-resistant depression Rowan DunneFebruary 1, 2023